<?xml version='1.0' encoding='utf-8'?>
<document id="11856903"><sentence text="3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient." /><sentence text="An intense debate has developed as to the risk-benefit ratio of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) following the withdrawal of cerivastatin"><entity charOffset="161-173" id="DDI-PubMed.11856903.s2.e0" text="cerivastatin" /></sentence><sentence text=" The development of rhabdomyolysis in cerivastatin-treated patients should have surprised few since myotoxicity is an accepted class effect of statins" /><sentence text=" What has sprung from the cerivastatin experience though is a concern for other members of this class"><entity charOffset="26-38" id="DDI-PubMed.11856903.s4.e0" text="cerivastatin" /></sentence><sentence text=" Such misgivings, although understandable, are ill advised" /><sentence text=" Without question, differences exist in the risk of rhabdomyolysis occurrence amongst the various statins" /><sentence text=" In this regard, pravastatin and fluvastatin are least likely to produce rhabdomyolysis, which, in part, relates to the fact they are not metabolized by the cytochrome P450 3A4 pathway"><entity charOffset="17-28" id="DDI-PubMed.11856903.s7.e0" text="pravastatin" /><entity charOffset="33-44" id="DDI-PubMed.11856903.s7.e1" text="fluvastatin" /><pair ddi="false" e1="DDI-PubMed.11856903.s7.e0" e2="DDI-PubMed.11856903.s7.e0" /><pair ddi="false" e1="DDI-PubMed.11856903.s7.e0" e2="DDI-PubMed.11856903.s7.e1" /></sentence><sentence text=" When muscle damage occurs with statins it is most often the result of a drug-drug interaction rather than a specific adverse response to statin monotherapy" /><sentence text=" Such drug-drug interactions increase plasma concentrations of a statin and thereby increase the risk of myotoxicity" /><sentence text=" A growing consensus exists which supports an expanded use of statins in a range of patient groups including the renal failure patient" /><sentence text=" Polypharmacy and altered drug metabolism increase the risk of myotoxicity, albeit to an ill-defined degree, in this population" /><sentence text=" Many factors should enter into the choice of a statin in the multiply medicated renal failure patient" /><sentence text="" /></document>